Drug intelligence / Profile preview

GCS002

Development stage: Preclinical
Lead developer: Glen Clova Scientific
Modality: Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics

Overview

GCS002 is a preclinical biologic drug candidate being developed for the treatment of atopic dermatitis. It is part of Glen Clova Scientific’s pipeline, which leverages virus-like particle (VLP) technology to create active biologic drugs targeting chronic inflammatory and autoimmune disorders. The VLP-based approach aims to modulate immune responses, with GCS002 specifically focused on interleukin-13 (IL-13), a cytokine implicated in the pathogenesis of atopic dermatitis[2][3][9]. The drug is currently in preclinical development.

Targets

IL-13 (Interleukin-13)

Beyond the preview

Go deeper on GCS002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GCS002.

Explore the full profile